155 related articles for article (PubMed ID: 23819639)
1. The association between XPC Lys939Gln gene polymorphism and urinary bladder cancer susceptibility: a systematic review and meta-analysis.
Dou K; Xu Q; Han X
Diagn Pathol; 2013 Jul; 8():112. PubMed ID: 23819639
[TBL] [Abstract][Full Text] [Related]
2. An association between XPC Lys939Gln polymorphism and the risk of bladder cancer: a meta-analysis.
Zhang Y; Wang X; Zhang W; Gong S
Tumour Biol; 2013 Apr; 34(2):973-82. PubMed ID: 23269608
[TBL] [Abstract][Full Text] [Related]
3. XPC Lys939Gln polymorphism contributes to colorectal cancer susceptibility: evidence from a meta-analysis.
Peng Q; Lao X; Tang W; Chen Z; Li R; Qin X; Li S
Diagn Pathol; 2014 Jun; 9():120. PubMed ID: 24947936
[TBL] [Abstract][Full Text] [Related]
4. XPC gene polymorphisms contribute to bladder cancer susceptibility: a meta-analysis.
Dai QS; Hua RX; Zeng RF; Long JT; Peng ZW
Tumour Biol; 2014 Jan; 35(1):447-53. PubMed ID: 23918308
[TBL] [Abstract][Full Text] [Related]
5. Current evidences on XPC polymorphisms and gastric cancer susceptibility: a meta-analysis.
Peng Q; Chen Z; Lu Y; Lao X; Mo C; Li R; Qin X; Li S
Diagn Pathol; 2014 May; 9():96. PubMed ID: 24886180
[TBL] [Abstract][Full Text] [Related]
6. Association of MTHFR Ala222Val (rs1801133) polymorphism and breast cancer susceptibility: An update meta-analysis based on 51 research studies.
Yu L; Chen J
Diagn Pathol; 2012 Dec; 7():171. PubMed ID: 23217001
[TBL] [Abstract][Full Text] [Related]
7. Association of XPC Polymorphisms with Cutaneous Malignant Melanoma Risk: Evidence from a Meta-Analysis.
Asadian F; Niktabar SM; Ghelmani Y; Kargar S; Akbarian E; Emarati SA; Sadeghizadeh-Yazdi J; Neamatzadeh H
Acta Medica (Hradec Kralove); 2020; 63(3):101-112. PubMed ID: 33002396
[TBL] [Abstract][Full Text] [Related]
8. Quantitative assessment of the association between XPC Lys939Gln polymorphism and cutaneous melanoma risk.
Zhou L; Lu Y; Yang G; Wu J
Tumour Biol; 2014 Feb; 35(2):1427-32. PubMed ID: 24277375
[TBL] [Abstract][Full Text] [Related]
9. Poly (AT) deletion/insertion polymorphism of the XPC gene contributes to urinary system cancer susceptibility: a meta-analysis.
Dai QS; Hua RX; Zhang R; Huang YS; Hua ZM; Yun CT; Zeng RF; Long JT
Gene; 2013 Oct; 528(2):335-42. PubMed ID: 23892089
[TBL] [Abstract][Full Text] [Related]
10. Association between CCND1 and XPC polymorphisms and bladder cancer risk: a meta-analysis based on 15 case-control studies.
Wang Y; Li Z; Liu N; Zhang G
Tumour Biol; 2014 Apr; 35(4):3155-65. PubMed ID: 24264314
[TBL] [Abstract][Full Text] [Related]
11. Current evidences on XPC polymorphisms and breast cancer susceptibility: a meta-analysis.
Zheng W; Cong XF; Cai WH; Yang S; Mao C; Zou HW
Breast Cancer Res Treat; 2011 Aug; 128(3):811-5. PubMed ID: 21318603
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in the XPC gene affect urinary bladder cancer risk: a case-control study, meta-analyses and trial sequential analyses.
Sankhwar M; Sankhwar SN; Bansal SK; Gupta G; Rajender S
Sci Rep; 2016 Jun; 6():27018. PubMed ID: 27246180
[TBL] [Abstract][Full Text] [Related]
13. Associations between polymorphisms of the XPC gene and lung cancer susceptibility: a meta-analysis.
Zhu ML; Hua RX; Zheng L
Tumour Biol; 2014 Apr; 35(4):2931-9. PubMed ID: 24375193
[TBL] [Abstract][Full Text] [Related]
14. XPC gene variants: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy.
Gangwar R; Mandhani A; Mittal RD
J Cancer Res Clin Oncol; 2010 May; 136(5):779-86. PubMed ID: 19924443
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of the XPC gene may contribute to the risk of head and neck cancer: a meta-analysis.
Zhang Y; Li Z; Zhong Q; Zhou W; Chen X; Chen X; Fang J; Huang Z
Tumour Biol; 2014 Apr; 35(4):3917-31. PubMed ID: 24338715
[TBL] [Abstract][Full Text] [Related]
16. XPC Lys939Gln and Ala499Val polymorphisms in colorectal cancer susceptibility: a meta-analysis of case-control studies.
Liu C; Yin Q; Ying M; Lin J; Li L; Jiao G; Wang M; Wang Y
Mol Biol Rep; 2014 Feb; 41(2):1171-8. PubMed ID: 24385304
[TBL] [Abstract][Full Text] [Related]
17. Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer.
Zhu Y; Lai M; Yang H; Lin J; Huang M; Grossman HB; Dinney CP; Wu X
Carcinogenesis; 2007 Mar; 28(3):698-703. PubMed ID: 17052994
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis of evidences on XPC polymorphisms and lung cancer susceptibility.
Liu C; Yin Q; Hu J; Li L; Zhang Y; Wang Y
Tumour Biol; 2013 Apr; 34(2):1205-13. PubMed ID: 23381646
[TBL] [Abstract][Full Text] [Related]
19. Quantitative assessment of the association between MHTFR C677T (rs1801133, Ala222Val) polymorphism and susceptibility to bladder cancer.
Xu W; Zhang H; Wang F; Wang H
Diagn Pathol; 2013 Jun; 8():95. PubMed ID: 23773402
[TBL] [Abstract][Full Text] [Related]
20. The polyAT, intronic IVS11-6 and Lys939Gln XPC polymorphisms are not associated with transitional cell carcinoma of the bladder.
Sak SC; Barrett JH; Paul AB; Bishop DT; Kiltie AE
Br J Cancer; 2005 Jun; 92(12):2262-5. PubMed ID: 15886698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
